The PubMed record lists the article title as “BCLXL blockade rewires cell fate to overcome PARP inhibitor resistance in ovarian cancer.” The title highlights three central elements: the molecular target BCLXL, the therapeutic class PARP inhibitor, and the clinical context ovarian cancer. These terms reflect the reported focus of the paper as indexed on PubMed.
The publication is a multi‑author study with contributions from investigators affiliated with Mayo Clinic. Departments represented in the PubMed entry include:
The author list on the PubMed record includes Annapoorna Venkatachalam, Annabella R Strathman, Xianon Hou, Cristina Correia, X Wei Meng, Cordelia D McGehee, Emily A Balczewski, Laura N Duffield, Olivia K Rossman, Clara Wong, Haiming Dai, Rachel M Hurley, Jill M Wagner, Saloni Singh, Karen S Flatten, Kevin L Peterson, Paula A Schneider, Silvana B De Lorenzo, Melissa C Larson, Ann L Oberg, Andrea E Wahner Hendrickson, Xinyan Wu, Akhilesh Pandey, Hu Li, S John Weroha, and Scott H Kaufmann, among others as listed in the PubMed record.
The PubMed entry reports the following bibliographic details:
These identifiers permit direct retrieval of the publisher version or other indexed copies for full text inspection.
The PubMed record indicates that two authors contributed equally to the work (notation shown in the author list). The record also provides a corresponding author contact: Scott H Kaufmann, with an email address listed in the PubMed metadata (Kaufmann.Scott@Mayo.edu). Use the corresponding author contact or the journal site to request clarifications or access supplementary materials when needed.
The PubMed page includes standard navigation links for Title & authors, Abstract, Conflict of interest statement, References, MeSH terms, and Substances. However, the source content provided here does not include the article abstract or the body of the paper. As a result, the following were not available in this source and are therefore not described here:
Because these items are absent from the provided PubMed snippet, no attempt has been made to infer or summarize study findings beyond what the title states.
To evaluate the study’s evidence and apply its findings in clinical or research contexts, retrieve the full text via one of these routes:
Suggested citation elements from the PubMed record:
Venkatachalam A, Strathman AR, Hou X, et al. BCLXL blockade rewires cell fate to overcome PARP inhibitor resistance in ovarian cancer. Signal Transduct Target Ther. 2026 Sep 21;11(1):393. doi:10.1038/s41392-026-02870-7. PMID: 42764286.
This rewritten summary relies exclusively on the PubMed metadata supplied. The PubMed snippet available here does not include the abstract, methods, results, figures, or discussion. Therefore, no experimental details, quantitative outcomes, or conclusions beyond the title can be reported without consulting the full article. Clinicians, researchers, and other readers should review the complete published paper for rigorous appraisal, appraisal of study validity, and assessment of potential clinical or translational impact.
If you would like, I can attempt to retrieve and summarize the abstract and main findings from the PubMed full record or the publisher site (if accessible), but that requires access to the text beyond the metadata shown in this source.